ストックスクリーナーアプリを入手
3.98
2.05%
0.08
プレマーケット:
4.04
0.06
+1.51%
Polypid Ltd (PYPD) 最新ニュース
PolyPid Ltd (PYPD) Balance Sheet - TradingKey
PolyPid Ltd (PYPD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PYPD|PolyPid Ltd|Price:3.950|Chg%:+0.050 - TradingKey
PYPD|PolyPid Ltd|Price:4.240| - TradingKey
PolyPid Ltd (PYPD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PolyPid Ltd (PYPD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PolyPid Ltd (PYPD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PolyPid Ltd (PYPD) Institutional Confidence - TradingKey
PolyPid Ltd (PYPD) Valuation: PE, PB & Fair Value Analysis - TradingKey
PolyPid Ltd (PYPD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PolyPid Ltd (PYPD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
PYPD|PolyPid Ltd|Price:3.900|Chg%:-0.340 - TradingKey
Antibacterial Drug Partnership Accelerates PolyPid Commercial Path - Streetwise Reports
PolyPid, Azurity Sign US$330M Deal for D-PLEX100 - Streetwise Reports
H.C. Wainwright Maintains PolyPid(PYPD.US) With Buy Rating, Maintains Target Price $13 - Moomoo
H.C. Wainwright reiterates Buy on PolyPid stock, $13 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy on PolyPid stock, $13 target - Investing.com UK
PolyPid price target lowered to $12 from $13 at Craig-Hallum - TipRanks
PYPD Reiterates by HC Wainwright & Co. -- Price Target Maintained at $13 - GuruFocus
Azurity Pharmaceuticals Announces Plans To Commercialize D-PLEX100 In The United States And Canada Through Exclusive Partnership With PolyPid - marketscreener.com
Roth Capital reaffirms Buy on PolyPid after exc... - Pluang
PolyPid, Azurity sign surgical site infection drug deal - Reuters
PolyPid, Azurity Pharmaceuticals Agree to Exclusive Commercial Partnership in US and Canada - Contract Pharma
Roth says Azurity deal validates D-PLEX100, sees limited near-term revenue - TipRanks
PolyPid Ltd. (PYPD) Faces Sharp Decline: Navigating Key Support LevelsQuality ETF - dars.gov.et
PolyPid Locks in a Transformative Deal Worth Over $320 Million, With Additional Major Royalty Potential - TipRanks
Azurity Announces Plans to Commercialize D-PLEX100 in the U.S. and Canada through Exclusive Partnership with PolyPid - The Manila Times
Israeli PolyPid signs $320 million deal to sell drug preventing surgical infections in US, Canada - The Jerusalem Post
PolyPid signs $320M deal with Azurity for D-PLEX100 in U.S., Canada - Investing.com South Africa
PolyPid Strikes Azurity Commercialization Deal for D-PLEX100 in U.S. and Canada - TipRanks
PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada - The Manila Times
PolyPidU.S. Launch of D-Plex100 Targeted f - Moomoo
PolyPid's D-PLEX100 Shows 60% Lower Surgical Infection Risk in Phase 3 - Stock Titan
Polypid Locks In A Transformative Deal Worth Over $320 Million, With Additional Major Royalty Potential - Menafn
PolyPid (PYPD) awards director 9,132 stock options vesting through 2030 - Stock Titan
PolyPid (NASDAQ: PYPD) grants 46,000 stock options to U.S. COO - Stock Titan
PolyPid (PYPD) awards CFO 49,000 stock options at $4.46 - Stock Titan
PolyPid Ltd. (PYPD) grants director 9,132 stock options at 4.46 - Stock Titan
PolyPid (PYPD) awards director 9,132 stock options at $4.46 - Stock Titan
PolyPid (PYPD) grants director Dror-Darwish Nir 9,132 stock options at $4.46 - Stock Titan
PolyPid (PYPD) director awarded 9,132 stock options at $4.46 strike price - Stock Titan
PolyPid (PYPD) CEO receives grant of 149,000 stock options - Stock Titan
PolyPid | 4: Statement of changes in beneficial ownership of securities-Officer Missulawin Jonathan - Moomoo
PolyPid Ltd. (PYPD) boosts option pool by 1.5M shares and clears CEO grant - Stock Titan
PolyPid (PYPD) Climbs 6% as Biotech Stock Tests Key ResistanceAndrews Pitchfork - dars.gov.et
PolyPid (PYPD) Climbs 3.97% as Shares Test Key Resistance ZoneAI Trade Signals - dars.gov.et
PolyPid Shares Slip 4% as Stock Tests Key Support LevelsThrowback Trade - dars.gov.et
PolyPid (PYPD) The Citizens Life Sciences Conference 2026 Summary - Quartr
PolyPid (PYPD) Lytham Partners Spring 2026 Investor Conference Summary - Quartr
PolyPid Ltd stock and its pipeline. A closer look at the drug-delivery specialist - ad-hoc-news.de
PYPDPolypid Ltd Latest SEC Filings - Finviz
Price to sales forward of PolyPid Ltd. – NASDAQ:PYPD - TradingView
Price to earnings forward of PolyPid Ltd. – NASDAQ:PYPD - TradingView
Enterprise value to revenue forward of PolyPid Ltd. – NASDAQ:PYPD - TradingView
Price to book forward of PolyPid Ltd. – NASDAQ:PYPD - TradingView
PolyPid Ltd. (PYPD) Surges 4.6%, Approaches Key Resistance at $5.22Exhaustion Gap - dars.gov.et
PYPD Forecast — Price Target — Prediction for 2027 - TradingView
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):